Gt Biopharma Inc   (GTBP)
Other Ticker:  
Price: $4.4000 $0.18 4.265%
Day's High: $4.46 Week Perf: 11.39 %
Day's Low: $ 4.22 30 Day Perf: -25.93 %
Volume (M): 3 52 Wk High: $ 21.90
Volume (M$): $ 13 52 Wk Avg: $8.82
Open: $4.24 52 Wk Low: $3.52

 Market Capitalization (Millions $) 180
 Shares Outstanding (Millions) 41
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -10
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Gt Biopharma Inc
Gt Biopharma Inc is a biotechnology company that specializes in the development and commercialization of immunotherapies for the treatment of various cancers. The company focuses on targeting and eliminating cancer cells using its proprietary platforms, including its proprietary TriKE technology. TriKE is a combination protein that acts as a bridge between natural killer (NK) cells and cancer cells, enhancing the immune response against cancer. Gt Biopharma aims to provide innovative and effective therapies to improve patient outcomes in the field of oncology.

   Company Address: 8000 Marina Blvd Brisbane 94005 CA
   Company Phone Number: 919-4040   Stock Exchange / Ticker: NASDAQ GTBP
   GTBP is expected to report next financial results on March 29, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Gt Biopharma Inc

GTBP Reports Impressive Operating Surplus of $3.122 Million in Third Quarter Earnings Season

The stock market has always been a dynamic and exciting place, filled with ups and downs that keep investors on their toes. Today, we turn our attention to the Major Pharmaceutical Preparations industry and delve into the third quarter of 2023 numbers. Specifically, we examine Gt Biopharma Inc's financial report from July to September 30, 2023, which showcased an operating surplus of $3.122 million.
It's important to note that Gt Biopharma Inc has not cited any revenue yet, making the operating surplus even more impressive. As industry reporters analyze these figures, the prevailing situation of the organization becomes clearer. To truly understand the significance of the third quarter of 2023 earnings season, let's compare it with the same period in 2022.

Gt Biopharma Inc

Surprising Profit Surge: Gt Biopharma Inc Generates $3.6 Million in Operating Income, Outperforming Expectations

As an avid investor with a keen eye for potential opportunities, I have been closely monitoring the financial results of Gt Biopharma Inc during the earnings cycle of April to June 30, 2023. While the majority of investors did not hold high hopes for significant changes within the business, the reported operating income of $3.621 million in the same period has certainly sparked interest and raised eyebrows.
Notably, Gt Biopharma Inc has demonstrated an increase in operating income compared to the second quarter of 2022, where it reported $3.014 million. Despite still developing its business model, the company has managed to efficiently trim the diminishing returns in the April to June 30, 2023 interval to $-1.992 million, compared to the $-2.979 million from the previous year.

Gt Biopharma Inc

Gt Biopharma Inc Faces Precarious Future as Financial Woes Pile Up

Gt Biopharma Inc is facing a bleak future based on its financial performance in the fiscal period ending March 31, 2023. The company recorded a loss per share of $-0.01 per share, which is a reduction from the results of $-0.17 per share in the previous year reporting season. However, despite the slight improvement, this should not be an encouragement to investors since the financial performance of Gt Biopharma Inc is still in a precarious state.
In the prior reporting season, Gt Biopharma Inc realized $-0.22 per share, and the income per share improved from $-0.22 per share. One might think that the company?s performance would have gotten better since its income per share improved; however, the losses per share remain alarmingly high. The fiscal first quarter of 2023 saw the company report a net loss of $-0.227 million, compared to a deficit of $-5.453 million in the comparable reporting season a year ago. This performance signals that the company is not likely to recover soon from its current financial woes.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com